EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toll‐Like Receptor Blockage by TIP‐1 and MIP‐2 Treatment Mitigates Inflammation in a Mouse Model of Adult‐Onset Still's Disease or Still's Disease

Mi-Hyun Ahn, Yang Seon Choi, Sang-Won Lee, Sangdun Choi, Hyoun-Ah Kim iD

European Journal of Immunology · 2025

DOI: 10.1002/eji.202451227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Mi-Hyun Ahn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea. Hauptthemen laut MEDLINE: Still's Disease, Adult-Onset, Inflammation, Chemokine CXCL2, Toll-Like Receptors. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inflammatory response triggered by Toll‐like receptors (TLRs) may implicated in the development of the pathogenesis of adult‐onset Still's disease (AOSD). This study evaluated the efficacy of TLR inhibitor peptides, specifically TLR inhibitor peptide 1 (TIP‐1) and MAL/MyD88 inhibitory peptide 2 (MIP‐2) in animal models of AOSD. THP‐1 cells were stimulated with TLR agonists and treated with TIP‐1 or MIP‐2. Interferon (IFN)‐γ knock‐out mice were induced with AOSD‐like symptoms using Mycobacterium mixed with Freund's complete adjuvant (CFA), then treated with the peptides. THP‐1 cells treated with TIP‐1 and MIP‐2 showed significantly decreased expression of TLRs agonist‐induced MyD88 and phosphorylated NF‐κB, except TLR9 agonists. Furthermore, the peptides resulted in a significant decrease in the concentrations of interleukin (IL)‐1β and IL‐6 in the culture supernatants, except TLR9 agonists. In animal models of AOSD, treatment with inhibitor peptides significantly improved their clinical symptoms. The administration of these peptides resulted in a significant decrease in serum levels of IL‐1β and IL‐18. The expression of inflammatory cytokines were downregulated in the spleen and lymph node of TIP‐1 and MIP‐2 treated mice. These findings suggest that TIP‐1 and MIP‐2 may be effective candidates for AOSD treatment, as they have broad specificity for TLRs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Still's Disease, Adult-OnsetInflammationChemokine CXCL2Toll-Like ReceptorsAnimalsMiceDisease Models, AnimalHumansMice, KnockoutTHP-1 CellsToll-Like Receptor 9Myeloid Differentiation Factor 88Interferon-gammaMice, Inbred C57BL

Stichwörter der Autor:innen

MyD88TLR inhibitor peptidesToll‐like receptorsadult‐onset Still's diseaseinflammation

Substanzen

Chemokine CXCL2Toll-Like ReceptorsToll-Like Receptor 9Myeloid Differentiation Factor 88Interferon-gamma

Autor:innen und Institutionen

  • Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea.
  • Department of Molecular Science and Technology, Ajou University, Suwon, South Korea.

ORCID-Profile: Hyoun-Ah Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Ahn, M. H., Choi, Y. S., Lee, S. W., Choi, S., & Kim, H. A. (2025). Toll‐Like Receptor Blockage by TIP‐1 and MIP‐2 Treatment Mitigates Inflammation in a Mouse Model of Adult‐Onset Still's Disease or Still's Disease. European Journal of Immunology. https://doi.org/10.1002/eji.202451227

Vancouver

Ahn MH, Choi YS, Lee SW, Choi S, Kim HA. Toll‐Like Receptor Blockage by TIP‐1 and MIP‐2 Treatment Mitigates Inflammation in a Mouse Model of Adult‐Onset Still's Disease or Still's Disease. European Journal of Immunology. 2025. doi:10.1002/eji.202451227

BibTeX
@article{Ahn2025,
  author = {Ahn, Mi-Hyun and Choi, Yang Seon and Lee, Sang-Won and Choi, Sangdun and Kim, Hyoun-Ah},
  title = {Toll‐Like Receptor Blockage by TIP‐1 and MIP‐2 Treatment Mitigates Inflammation in a Mouse Model of Adult‐Onset Still's Disease or Still's Disease},
  journal = {European Journal of Immunology},
  year = {2025},
  doi = {10.1002/eji.202451227}
}
Kostenlos starten →